Literature DB >> 35174956

Pregnancy outcomes of rare autosomal trisomies results in non-invasive prenatal screening: clinical follow-up data from a single tertiary centre.

Ying Lin1, Ping Hu1, Hang Li1, Chunyu Luo1, Dong Liang1, Zhengfeng Xu1.   

Abstract

This study was performed to assess the association between detection of rare autosomal trisomies (RATs) by non-invasive prenatal screening (NIPS) and adverse pregnancy outcomes. We retrospectively analyzed women with high-risk RATs results from January 2014 to December 2020. The women's clinical information was collected, and their pregnancy outcomes were compared with those of women with low-risk results. In total, 151 (0.24%) RATs results were reported among 62,752 NIPS examinations. Sixty-five women chose to undergo amniocentesis for confirmation, which revealed 3 cases of true fetal mosaicism for RATs and a positive predictive value of 4.6% (3/65). Among the 139 women with available outcomes, 26 (18.7%) had a preterm birth, 10 (7.2%) underwent pregnancy termination because of fetal defects and 5 (3.6%) had miscarriages. Interestingly, compared with the control group, pregnancies in which NIPS revealed trisomy 16 (T16), T22, T9 and T2 were at higher risk of adverse outcomes, including preterm birth, miscarriage and ultrasound abnormalities. However, the risk of adverse outcomes was comparable between the control group and pregnancies with positive results of T7, T3, T8 and T20. In summary, the risk of adverse pregnancy outcomes was higher in women with specific RATs-positive NIPS results. Pregnancies with T16, T22, T9 and T2 results, even if false-positive, should be considered high-risk pregnancies.
© 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  non-invasive prenatal screening; pregnancy outcomes; rare autosomal trisomies

Mesh:

Year:  2022        PMID: 35174956      PMCID: PMC8995450          DOI: 10.1111/jcmm.17245

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


INTRODUCTION

During the last decade, non‐invasive prenatal screening (NIPS) has become a broadly applied strategy for common aneuploidies. , Because massively parallel sequencing‐based NIPS sequences cell‐free DNA from all chromosomes in maternal plasma, it is theoretically able to detect aneuploidies of all chromosomes, including rare autosomal trisomies (RATs). However, whether NIPS should extend to the detection of RATs in clinical practice remains controversial. , , , , One important reason for this controversy is that the sensitivity, specificity, false‐positive rate and pregnancy outcome information of the RATs results obtained by NIPS are still limited. Therefore, the clinical benefits of these results remain unclear. Several previous researchers have reported the RATs results obtained by NIPS, and their data showed that most of these results were false‐positive because of confined placental mosaicism. , , In addition, different conclusions have been drawn regarding the clinical significance of RATs results. In some studies, RATs were associated with fetal growth abnormalities as well as higher miscarriage rates. , However, data from other studies showed that RATs were mostly associated with normal pregnancy outcomes. Although the data regarding RATs are still limited, it has become necessary to clarify the clinical significance of RATs detected by NIPS because of the broadening acceptance of NIPS in clinical practice. In this study, we retrospectively analyzed 151 RATs results from 62,752 NIPS examinations performed in our centre from January 2014 to December 2020. We reviewed the NIPS results as well as the follow‐up records and compared the pregnancy outcomes with 10,397 low‐risk NIPS results to evaluate the clinical significance of RATs results and to determine whether these results are associated with adverse pregnancy outcomes.

MATERIALS AND METHODS

Recruitment criteria

This study involved pregnant women who underwent NIPS testing for genome‐wide cell‐free DNA screening in the Medical Genetics Center of the Affiliated Obstetrics and Gynecology Hospital with Nanjing Medical University from January 2014 to December 2020. The inclusion criteria for this study were a pregnancy with a high‐risk RATs report and complete clinical information, and the exclusion criterion was loss to follow‐up. This study was approved by the institutional review board of the Nanjing Maternity and Child Health Care Hospital (approval number NFLZ2019‐KY‐004).

NIPS examinations

Five millilitres of maternal peripheral blood was collected from each participant using EDTA anticoagulant tubes and centrifuged within 8 hours to extract the plasma. The details of the procedure were similar to those described in our previous report. , A library was constructed using the BGI protocol and sequenced using the BGISEQ‐500 platform (BGI Group). The cut‐off fetal fraction was set at 3.5%. Fetal chromosomal trisomies for chromosomes 13, 18, 21, X and Y as well as other genome‐wide RATs and subchromosome copy number variants were analyzed.

Outcome collection

We retrospectively analyzed the data of women with high‐risk RATs results. The following data regarding these women's maternal and pregnancy characteristics were collected from the laboratory database and clinical records: maternal age, gestational age (GA) at the time of NIPS, NIPS results and pregnancy outcomes (cytogenetic results, ultrasound examination results, miscarriage, termination of pregnancy, GA at the time of delivery and newborn physical examination results). Birthweight percentile was calculated according to NICHD (national institute of child health and human development) (Asian) charts. Preterm was defined as delivery at <37 weeks of gestation. The pregnancy outcomes for women with low‐risk NIPS results in 2019 were used as comparative controls. Women who had pregnancies with RATs detected by NIPS were recommended to undergo confirmatory invasive prenatal diagnosis using amniocentesis followed by chromosomal microarray analysis. A detailed flow diagram of the study design is shown in Figure 1.
FIGURE 1

Flow of study design. NIPS, non‐invasive prenatal screening; RATs, rare autosomal trisomies

Flow of study design. NIPS, non‐invasive prenatal screening; RATs, rare autosomal trisomies

Statistical analysis

Continuous variables such as maternal age and GA are expressed as mean ± standard deviation. The incidence of RATs and pregnancy outcome results are expressed as number and percentage. Differences in outcomes between the RATs group and the low‐risk NIPS group were compared using the χ 2 test or Fisher's exact test. A p value of <0.05 was considered statistically significant. Statistical analysis was performed using SPSS 19.0 (IBM Corp).

RESULTS

Detection of RATs by NIPS

We retrospectively reviewed the data of 62,752 NIPS examinations performed in our centre from January 2014 to December 2020. The mean age of these pregnant women was 31.6 ± 4.8 years, and the mean GA was 17.7 ± 2.5 weeks. In total, 151 RATs results were reported (0.24%). Trisomy 7 (T7), T16, T3, T8, T22, T20, T9 and T2 were the most frequently detected RATs, whereas T4, T12, T17, and T19 were not detected (Figure 2).
FIGURE 2

Distribution of rare autosomal trisomies. T, trisomy

Distribution of rare autosomal trisomies. T, trisomy

Confirmation of RATs results

Among the 151 RATs cases, 65 women chose to undergo amniocentesis. The results showed three cases of confirmed true fetal mosaicism (TFM) for RATs, including one case of mosaic T9 and two cases of mosaic T22. Therefore, the positive predictive value of RATs was 4.6% (3/65). We also found six cases of uniparental disomy (UPD), including two cases involving chromosome 2 and four cases involving chromosome 16. There was an incidental finding of one case with confirmed fetal 22q11.2 microduplication. The other 55 (84.6%) women showed a normal karyotype in their amniocentesis results. The detailed data are shown in Table 1.
TABLE 1

Clinical outcome data of 65 RATs cases with confirmation

Case No.Gestation at NIPS (wk)Age at NIPS (yrs)Fetal fraction %NIPS resultPrenatal diagnosis resultsSummary of pregnancy outcome
112.573911.099T1normallive birth
214.86387.711T2

arr[hg19] 2q24.3(164,883,185–165,471,899) ×4

arr[hg19] 2p14p11.2(68,531,636–87,053,152) ×2 hmz

arr[hg19] 2q32.2q37.1(191,219,849–232,206,620) ×2 hmz

UPD, TOP
318.0035noneT2arr[hg19] 2p25.3q37.3(12,770–242,782,257) ×2 hmzUPD, preterm birth
415.43283.872T3normalpreterm birth
522.43269.271T3normallive birth
618.86357.931T3normallive birth
714.71279.675T3normallive birth, full‐term infants small for gestational age (2100 g)
813.713311.73T3normallive birth
916.713110.625T3normallive birth
1013.00234.956T3normallive birth
1120.4344noneT3normallive birth
1216.0031noneT3normallive birth
1317.2930noneT5normallive birth
1418.71337.623T7normallive birth
1514.293114.951T7normallive birth
1613.86287.438T7normallive birth
1713.86287.438T7normallive birth
1816.143315.05T7normallive birth
1918.00277.252T7normallive birth
2014.292712.527T7normallive birth
2117.293211.037T7normalTOP for personal reason
2222.863516.513T7normallive birth
2317.003113.716T7normallive birth
2419.572813.098T7normallive birth
2519.57328.602T7normallive birth
2619.432611.385T7normallive birth, full‐term infants small for gestational age (2400 g)
2717.71289.965T7normallive birth
2816.143710.299T7normallive birth
2918.712510.775T7normallive birth
3016.29388.312T8normallive birth
3119.712810.959T8normallive birth
3219.713122.302T8normallive birth
3316.57265.621T8normallive birth
3418.0027noneT8arr[hg19]9p21.3(25,071,212–25,600,438) ×3live birth
3516.14377.873T9normallive birth
3618.862611.665T9normallive birth
3718.29345.556T9arr[hg19] (9) ×2–3TFM, TOP
3815.86364.811T11normalpreterm birth
3915.29334.643T14normalTOP for personal reason
4015.71306.851T15normallive birth
4123.003513.305T16normallive birth
4219.573115.994T16normalsingle umbilical artery, preterm birth
4316.713611.058T16arr[hg19]16p13.3p13.2(94,807–8,418,576) ×2 hmzUPD, live birth
4418.432613.63T16arr[hg19]16q22.1q24.3(69,860,932–90,146,366) ×2 hmzUPD, preterm birth
4518.00325.505T16normallive birth
4616.864010.459T16normalpreterm birth
4718.86329.574T16normalmiscarriage
4816.00267.821T16normalpreterm birth
4918.0037noneT16arr[hg19]2p25.3q37.3(12,770–242,782,257) ×2 hmzUPD, preterm birth
5017.0027noneT16arr[hg19]16p13.3p13.12(110,582–8,590,518) ×2 hmzUPD, preterm birth
5117.5738noneT16normalabnormal ultrasound, TOP
5216.1435noneT16normallive birth
5312.86358.874T20normallive birth
5419.57378.255T20normallive birth
5518.86329.017T20normallive birth
5612.863015.852T20normallive birth
5720.143812.836T20normallive birth
5823.2934noneT20normalpreterm birth
5923.7145noneT20normalno outcome data
6018.713811.172T22normalpreterm birth
6117.432913.028T22arr[hg19] 22q11.21(18,919,477–21,464,764) ×3abnormal ultrasound, TOP
6218.003318.509T22normallive birth
6319.003311.295T22arr[hg19] (22) ×2–3TFM, TOP
6418.862916.377T22arr[hg19] (22) ×2–3TFM, miscarriage
6515.7127noneT22normalpreterm birth

GA, gestational age; NIPS, non‐invasive prenatal screening; RAT, rare autosomal trisomy; T, trisomy; TFM, true fetal mosaic; TOP, termination of pregnancy; UPD, uniparental disomy.

Clinical outcome data of 65 RATs cases with confirmation arr[hg19] 2q24.3(164,883,185–165,471,899) ×4 arr[hg19] 2p14p11.2(68,531,636–87,053,152) ×2 hmz arr[hg19] 2q32.2q37.1(191,219,849–232,206,620) ×2 hmz GA, gestational age; NIPS, non‐invasive prenatal screening; RAT, rare autosomal trisomy; T, trisomy; TFM, true fetal mosaic; TOP, termination of pregnancy; UPD, uniparental disomy.

Pregnancy outcome results

Among the 151 RATs cases, 147 (97.4%) women were successfully followed up to retrieve the pregnancy outcome. The results showed that eight (5.4%) women personally chose termination of pregnancy without medical indications. Among the other 139 pregnancies, 26 (18.7%) ended with preterm birth, 5 (3.6%) ended with miscarriage and 10 (7.2%) were terminated because of fetal defects including 6 ultrasound abnormalities, 1 confirmed case of fetal UPD and 3 confirmed cases of fetal chromosomal abnormalities. The other 98 (70.5%) pregnancies ended in full‐term live births with normal phenotypes. The detailed information of the RATs cases and their outcomes are shown in Table 1 and Table 2. Birthweight information was available in 107 of the 124 newborns. We found that 13 newborns were recorded with birthweight below 3rd percentile (13/107, 12.1%), including 7 cases of T16, 2 cases of T2 and single case of T3, T15, T20, T22, respectively (Table S1).
TABLE 2

Clinical outcomes for 147 cases with RATs results

TOP directlyUPDAbnormal ultrasound findingFetal abnormal chromosomeMiscarriagePreterm birthFull‐term birthTotal
Trisomy 100000112
Trisomy 202 a 100327
Trisomy 31000111417
Trisomy 500000022
Trisomy 600000101
Trisomy 71000023538
Trisomy 81000001415
Trisomy 9102110510
Trisomy 1000000044
Trisomy 1100000213
Trisomy 1410000023
Trisomy 1500000112
Trisomy 1614 b 20211 c 824
Trisomy 2000000178
Trisomy 222023 d 13211
Total866442297147

RAT, rare autosomal trisomy; TOP, termination of pregnancy; UPD, uniparental disomy.

Including 1 with preterm birth.

Including 3 with preterm birth, and 1 with full‐term birth.

Including 1 with neonatal demise.

Including 1 with miscarriage, and 1 with abnormal ultrasound findings.

Clinical outcomes for 147 cases with RATs results RAT, rare autosomal trisomy; TOP, termination of pregnancy; UPD, uniparental disomy. Including 1 with preterm birth. Including 3 with preterm birth, and 1 with full‐term birth. Including 1 with neonatal demise. Including 1 with miscarriage, and 1 with abnormal ultrasound findings.

Comparison of pregnancy outcomes between RATs results and low‐risk results

To further investigate the clinical significance of the RATs results, we compared the pregnancy outcomes of women with RATs results obtained by NIPS versus women with low‐risk NIPS results, which were used as the control group (Figure 1 summarizes the study design). We found that the risk of adverse outcomes, including miscarriage, ultrasound abnormalities and preterm birth, was significantly higher in the RATs group than in the control group (p < 0.05). We next focused on T7, T16, T3, T8, T22, T9, T20 and T2, which had higher detection rates than the other RATs in our cohort (Figure 2). Compared with the control group, the occurrence of miscarriage was significantly higher in women with T16 results; ultrasound abnormalities were significantly higher in women with T16, T22 and T9 results; and preterm birth was significantly higher in women with T16, T22 and T2 results. However, no significant difference in the occurrence of adverse outcomes was found between the control group and women with T7, T3, T8 and T20 results (Table 3).
TABLE 3

Comparison pregnancy outcomes of NIPS results between RATs group and control group

OutcomeControlRATsTrisomy 7Trisomy 16Trisomy 3Trisomy 8Trisomy 22Trisomy 9Trisomy 20Trisomy 2
n = 10,397 n = 147 p value n = 38 p value n = 24 p value n = 17 p value n = 15 p value n = 11 p value n = 10 p value n = 8 p value n = 7 p value
Miscarriage8440.034*0>0.99920.017*10.1300>0.99910.08610.0790>0.9990>0.999
Abnormal ultrasound finding8260.001*0>0.99920.016*0>0.9990>0.99920.003*2<0.001*0>0.99910.055
Preterm birth36526<0.001*20.38811<0.001*10.4560>0.99930.006*0>0.99910.24930.001*

NIPS, non‐invasive prenatal screening; RAT, rare autosomal trisomy. p values comparing pregnancy outcomes of NIPS between RATs group and control group are obtained from χ2 test or Fisher's exact test. *p < 0.05

Comparison pregnancy outcomes of NIPS results between RATs group and control group NIPS, non‐invasive prenatal screening; RAT, rare autosomal trisomy. p values comparing pregnancy outcomes of NIPS between RATs group and control group are obtained from χ2 test or Fisher's exact test. *p < 0.05

DISCUSSION

The potential clinical implications of detecting fetal RATs during prenatal testing are unclear, and most of these results to date have been obtained from chorionic villus sample (CVS) analysis. With the rapidly increasing application of NIPS, more RATs results are being obtained by this method; however, adequate outcome data with which to determine the clinical implication of these RATs results are still lacking. Because both NIPS and CVS analysis involve analyzing the genetic component of the placental trophoblastic cell lineage, NIPS results are considered comparable to CVS short‐term culture results. However, several differences still exist between CVS analysis and NIPS. Van Opstal et al. reported that NIPS is more sensitive to (low‐level) placental mosaicism involving the cytotrophoblast than in CVS analysis. Additionally, Benn et al.  showed that there was a significantly higher frequency of TFM among RATs ascertained by NIPS (9.8%) than CVS analysis (3.0%). These differences may result in different conclusions regarding the RATs results obtained by CVS analysis versus NIPS.  Therefore, it is beneficial to clarify the clinical implications of RATs detected by NIPS. The detection rate of RATs by NIPS reportedly ranges from 0.12% to 1.03%, and almost all RATs also exhibit mosaicism. However, there is no consensus regarding the association between RATs detected by NIPS and adverse pregnancy outcomes according to recent reports. , , , Pertile et al. reported that the presence of a RAT found by NIPS was associated with an increased risk of feto‐placental disease, including miscarriage, intrauterine fetal death, intrauterine growth restriction, TFM and UPD, and only 27% (14/52) of RATs with outcome data resulted in a normal live birth in their study. Scott et al. found that 16 (57.1%) of 28 cases of RATs had abnormal outcomes, including 6 miscarriages, 5 TFMs and 5 fetal structural anomalies on ultrasound. However, He et al. found no sonographic structural anomalies or TFM among 61 cases of RATs, and 54 cases were confirmed to have confined placental mosaicism. Pregnancy follow‐up showed that 95% of the women in their study had an uncomplicated pregnancy with the exception of two cases of intrauterine growth restriction (one case of T16 and one case of compound T7/8). In our study, 29.5% of RATs cases were associated with preterm birth, miscarriage, ultrasound abnormalities, TFM and UPD, and the other 70.5% of pregnancies ended in normal full‐term live births. These differences in RATs outcomes may be associated with the distribution of the GA at the time of NIPS. In the studies by Pertile et al. and Scott et al., most samples were collected in the first trimester, which was earlier than in the study by He et al. and the present study. On the other hand, a nuchal translucency scan or a second‐trimester ultrasound before blood sampling was mandatory in the study by He et al., which further reduced the number of high‐risk pregnancies compared with other studies. Finally, the small sample sizes in every study may have also contributed to the differences. T16 is the most frequently reported trisomy and might be associated with a risk of adverse pregnancy outcomes. , , Benn et al. reviewed six studies and found that 64.5% of pregnancies with T16 had fetal abnormalities, fetal growth restriction and miscarriage. Grati et al. extrapolated CVS data to NIPS and considered that only T16‐confined placental mosaicism had a strong association with an increased incidence of birthweight below the third percentile and preterm delivery, whereas other RATs were associated with a low incidence of adverse outcomes. Recently, Peng et al. found 5 true‐positive results and 9 false‐positive results among 14 cases of T16 detected by NIPS. Of the nine false‐positive cases, eight infants were born with a low birthweight. The authors also found two premature infants and considered that T16 pregnancies might be at higher risk for preterm delivery. In our study, a significant association was found between T16 and preterm delivery, miscarriage, and ultrasound abnormalities as compared with normal controls. Similar with previous reports, we also found T16 newborns have an increased incidence of low birthweight (43.8%, 7/16). According to the above results, genetic counselling and pregnancy management should be implemented when NIPS reveals T16, especially for preterm delivery. Like T16, T22 is also easily detectable and is potentially associated with adverse outcomes. , , Benn et al. identified 17 cases of T22 with outcome information available from recent reports, of which 10 experienced fetal loss, 2 were diagnosed with TFM, 1 was diagnosed with fetal growth restriction and 4 had an apparently normal outcome. Pescia et al. reported that 100% (3/3) of T22 results were confirmed to be associated with TFM among 19 cases of RATs detected by NIPS. Other studies have shown that fetuses with mosaicism for T22 at the time of amniocentesis can be associated with abnormal ultrasound findings. , , In our study, 33.3% (2/6) of T22 results were confirmed to be associated with TFM of T22, and T22 was associated with both ultrasound abnormalities and preterm delivery. Therefore, ultrasound and invasive prenatal diagnosis should be recommended for women with T22 results. T7 is the most common RAT, with a rate of 0.056% among NIPS examinations, and has a mostly favourable outcome. Zhu et al. reviewed 85 cases of T7 detected by NIPS. Among them, 88.2% were live births with a normal outlook; 14.1% had intrauterine growth restriction, preterm birth or low birth weight; 3.5% presented with ultrasound abnormalities; and no fetal loss was observed. He et al. analyzed 24 cases of T7 and reported that all had normal pregnancy outcomes, and T7 was not confirmed in any cases. Our results also showed no significant difference between the T7 group and control group. Additionally, like T7, the pregnancy outcomes of T3, T8 and T20 were generally satisfactory in our study. Therefore, caution is needed before performing any invasive procedures in pregnancies with these RATs, which may be associated with a favourable outcome. The main strength of this study is the relatively large number of RATs results with pregnancy outcomes from a single tertiary centre. We systematically and comprehensively expounded the relationship between various RATs detected by NIPS and adverse pregnancy outcomes for the first time, and our data showed that the associations and relevance for each chromosome were different. The results could be informative in clinical counselling and pregnancy management.

CONCLUSIONS

In this study, we retrospectively analyzed 151 RATs detected by NIPS and found that the chances of adverse outcomes, including miscarriage, ultrasound abnormalities and preterm birth, were significantly higher in the RATs group than the control group. Among the most frequent RATs, T16, T22, T9 and T2 were associated with adverse outcomes, and more intensive pregnancy monitoring should be provided for these special cases. Given the low positive predictive value and various outcomes, the question regarding whether it is beneficial to extend NIPS for RATs remains unanswered. More clinical data are needed to further evaluate the clinical implications of these RATs results.

CONFLICT OF INTEREST

The authors confirm that there are no conflicts of interests.

AUTHOR CONTRIBUTIONs

Ying Lin: Data curation (equal); Formal analysis (lead); Writing – original draft (equal); Writing – review & editing (equal). Ping Hu: Formal analysis (equal); Investigation (equal). Hang Li: Data curation (equal). Chunyu Luo: Investigation (equal). Dong Liang: Funding acquisition (equal); Project administration (equal); Writing – review & editing (equal). Zhengfeng Xu: Investigation (equal); Project administration (equal). Table S1 Click here for additional data file.
  21 in total

1.  Rare autosomal trisomies on non-invasive prenatal testing: not as adverse as expected.

Authors:  Y He; Y-H Liu; R-G Xie; S-A Liu; D-Z Li
Journal:  Ultrasound Obstet Gynecol       Date:  2019-12       Impact factor: 7.299

2.  Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of feto-placental disease.

Authors:  Mark D Pertile; Meredith Halks-Miller; Nicola Flowers; Catalin Barbacioru; Sarah L Kinnings; Darcy Vavrek; William K Seltzer; Diana W Bianchi
Journal:  Sci Transl Med       Date:  2017-08-30       Impact factor: 17.956

3.  Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies.

Authors:  Germaine M Buck Louis; Jagteshwar Grewal; Paul S Albert; Anthony Sciscione; Deborah A Wing; William A Grobman; Roger B Newman; Ronald Wapner; Mary E D'Alton; Daniel Skupski; Michael P Nageotte; Angela C Ranzini; John Owen; Edward K Chien; Sabrina Craigo; Mary L Hediger; Sungduk Kim; Cuilin Zhang; Katherine L Grantz
Journal:  Am J Obstet Gynecol       Date:  2015-10       Impact factor: 8.661

4.  Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA.

Authors:  Francesca Romana Grati; Jose Ferreira; Peter Benn; Claudia Izzi; Federica Verdi; Elena Vercellotti; Cristina Dalpiaz; Patrizia D'Ajello; Elisa Filippi; Nicola Volpe; Francesca Malvestiti; Federico Maggi; Giuseppe Simoni; Tiziana Frusca; Gaetana Cirelli; Gabriella Bracalente; Antonino Lo Re; Daniela Surico; Tullio Ghi; Federico Prefumo
Journal:  Genet Med       Date:  2019-08-08       Impact factor: 8.822

5.  Current controversies in prenatal diagnosis 2: Cell-free DNA prenatal screening should be used to identify all chromosome abnormalities.

Authors:  Lyn S Chitty; Louanne Hudgins; Mary E Norton
Journal:  Prenat Diagn       Date:  2018-02       Impact factor: 3.050

6.  Follow-Up Studies of cf-DNA Testing from 101 Consecutive Fetuses and Related Ultrasound Findings.

Authors:  Seher Basaran; Recep Has; Ibrahim Halil Kalelioglu; Birsen Karaman; Melike Kirgiz; Tahir Dehgan; Bilge Nihan Satkin; Tugba Sarac Sivrikoz; Atil Yuksel
Journal:  Ultraschall Med       Date:  2018-09-25       Impact factor: 6.548

7.  Origin and clinical relevance of chromosomal aberrations other than the common trisomies detected by genome-wide NIPS: results of the TRIDENT study.

Authors:  Diane Van Opstal; Merel C van Maarle; Klaske Lichtenbelt; Marjan M Weiss; Heleen Schuring-Blom; Shama L Bhola; Mariette J V Hoffer; Karin Huijsdens-van Amsterdam; Merryn V Macville; Angelique J A Kooper; Brigitte H W Faas; Lutgarde Govaerts; Gita M Tan-Sindhunata; Nicolette den Hollander; Ilse Feenstra; Robert-Jan H Galjaard; Dick Oepkes; Stijn Ghesquiere; Rutger W W Brouwer; Lean Beulen; Sander Bollen; Martin G Elferink; Roy Straver; Lidewij Henneman; Godelieve C Page-Christiaens; Erik A Sistermans
Journal:  Genet Med       Date:  2017-09-28       Impact factor: 8.822

8.  Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics.

Authors:  Anthony R Gregg; Brian G Skotko; Judith L Benkendorf; Kristin G Monaghan; Komal Bajaj; Robert G Best; Susan Klugman; Michael S Watson
Journal:  Genet Med       Date:  2016-07-28       Impact factor: 8.822

9.  Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies.

Authors:  Fuman Jiang; Jinghui Ren; Fang Chen; Yuqiu Zhou; Jiansheng Xie; Shan Dan; Yue Su; Jianhong Xie; Baomin Yin; Wen Su; Huakun Zhang; Wei Wang; Xianghua Chai; Linhua Lin; Hui Guo; Qiyun Li; Peipei Li; Yuying Yuan; Xiaoyu Pan; Yihan Li; Lifu Liu; Huifei Chen; Zhaoling Xuan; Shengpei Chen; Chunlei Zhang; Hongyun Zhang; Zhongming Tian; Zhengyu Zhang; Hui Jiang; Lijian Zhao; Weimou Zheng; Songgang Li; Yingrui Li; Jun Wang; Jian Wang; Xiuqing Zhang
Journal:  BMC Med Genomics       Date:  2012-12-01       Impact factor: 3.063

View more
  1 in total

1.  Pregnancy outcomes of rare autosomal trisomies results in non-invasive prenatal screening: clinical follow-up data from a single tertiary centre.

Authors:  Ying Lin; Ping Hu; Hang Li; Chunyu Luo; Dong Liang; Zhengfeng Xu
Journal:  J Cell Mol Med       Date:  2022-02-16       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.